Goldman Sachs reinstated coverage of Relay Therapeutics with a Buy rating and $20 price target. The firm cites the company’s positive Phase 2 data of selective PI3Kalpha inhibitor RLY-2608 + fulvestrant in PI3Kalpha-mutated HR+/HER2- breast cancer and its planned Phase 3 study initiation in 2025, the analyst tells investors in a research note. Notwithstanding the stock move after the data, Relay Therapeutics is seen as “undervalued” in the context of RLY-2608’s commercial opportunity, and the firm sees upside on further data/execution, Goldman Sachs added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RLAY:
- Relay Therapeutics announces $200M common stock offering
- Relay Therapeutics Announces Proposed Public Offering of Common Stock
- Relay Therapeutics price target raised to $17 from $14 at Barclays
- Palantir, Dell Technologies named to join S&P 500: Morning Buzz
- Relay Therapeutics’ RLY-2608 Shows Promise in Breast Cancer Trials